Evaluation of FES (16α-[18F]-fluoro-17β-estradiol) PET for (re)staging of patients with clinical (locally) advanced or locoregional recurrent estrogen receptor positive breast cancer. (October 2020) - Iqbal, R.; Mo, C.; Cysouw, M.C.F.; Glaudemans, A.W.J.M.; Hospers, G.A.P.; Schroder, C.P.; Venema, C.C.M.; Menke-van der Houven van Oordt, C.W.